DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Essential Hypertension

Intervention: Valsartan + amlodipine 40/2.5 mg (Drug); Valsartan + amlodipine 40/5 mg (Drug); Valsartan + amlodipine 80/2.5 mg (Drug); Valsartan + amlodipine 80/5 mg (Drug); Valsartan 40 mg (Drug); Valsartan 80 mg (Drug); Amlodipine 2.5 mg (Drug); Amlodipine 5 mg (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Novartis Pharmaceuticals

Official(s) and/or principal investigator(s):
Novartis Japan, Study Chair, Affiliation: Sponsor GmbH


The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2. 5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.

Clinical Details

Official title: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)

Secondary outcome:

Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)

Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)

Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)

Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)


Minimum age: 20 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion criteria

- Patients with essential hypertension measured by electronic hemodynamometer. - -

Patients must satisfy the following criteria. 1. MSDBP <110 mmHg and MSSBP <180 mmHg at Visit 1 2. MSDBP ≥ 90 mmHg and < 110 mmHg and MSSBP < 180 mmHg at Visit 2 3. MSDBP ≥ 95 mmHg and < 110 mmHg and MSSBP < 180 mmHg at Visit 3 4. The absolute difference in MSDBP between Visit 2 and 3 is ≤ 10 mmHg

- Male or female outpatients.

- Aged => 20 and =< 80 years (at the time of signing informed consent).

- Patients who have written informed consent to participate in this study.

Exclusion criteria

- Pregnant women, nursing (lactating) mothers, women suspected of being pregnant, or

women who wish to be pregnant during the study, women of child-bearing potential.

- Patients with secondary hypertension or suspected of having secondary hypertension.

- Patients with a history of malignant hypertension.

- Patients with an inability to completely discontinue all prior antihypertensive

medications safely for a period of 12 weeks as required by the protocol.

- Patients with or with a history of any of the following diseases or signs: Cardiac

disease, renal disease, cerebrovascular disorder

- Patients with a clinically significant allergy (asthma on pharmacotherapy, multi-drug

allergy, or drug-induced or food-induced anaphylactic reactions).

- Patients hypersensitive to AII receptor antagonists, calcium channel blockers or

dihydropyridine derivatives.

- Known moderate or malignant retinopathy.

- Patients with or with a history of pancreatitis. Patients with pancreatic injury, or

evidence of impaired pancreatic function/injury within 12 months of Visit 1.

- Patients with any surgical or medical condition which might significantly alter the

absorption, distribution, metabolism, or excretion of any drug.

- Patients with volume depletion based on the investigator's or subinvestigator's

clinical judgment using vital signs, skin turgor, moistness of mucous membrane and laboratory values.

- Patients who are found to have low Na and K (Na <130 mEq/L, K <3. 3mEq/L) or high in

these parameters (Na ≥ 152 mEq/L, K ≥ 5. 2 mEq/L) by laboratory tests at Visit 1.

- Patients with type I diabetes mellitus on treatment with insulin, or patients with

type II diabetes with poor glucose control defined as a glycosylated hemoglobin (HbA1c) > 8. 0% at Visit 1.

- Patients with or with a history of malignant tumors including leukemia and lymphoma,

treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or metastases (except for localized basal cell carcinoma of the skin).

- Patients with any severe, life-threatening disease within the past 5 years. Patients

with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

- Any surgical or medical condition, which in the opinion of the investigator or

subinvestigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirement of the study or completing the trial period.

- Patients who have with or with a history of drug or alcohol abuse within the last 2

years of Visit 1. Patients who have received other investigational product within 12 weeks of Visit 1.

- Any chronic inflammatory condition needing chronic anti-inflammatory drug therapy.

- Persons directly involved in the execution of this study.

- Patients who are considered unlikely to comply with the requirements specified in the

protocol by the investigator or subinvestigator.

Locations and Contacts

Novartis Pharmaceuticals, Tokyo 11111, Japan
Additional Information

Starting date: November 2006
Last updated: April 20, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017